A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol-Reference-Cited by-同舟云学术

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

Published:2021-12 Issue: Volume:27 Page:294-298
ISSN:2213-7165
Container-title:Journal of Global Antimicrobial Resistance
language:en
Short-container-title:Journal of Global Antimicrobial Resistance

Author:

Gatti Milo^ORCID,Bartoletti Michele^ORCID,Cojutti Pier Giorgio,Gaibani Paolo,Conti Matteo^ORCID,Giannella Maddalena,Viale Pierluigi,Pea Federico^ORCID

Publisher

Elsevier BV

Subject

Microbiology (medical),Immunology,Immunology and Allergy,Microbiology

Reference20 articles.

1. Managing Acinetobacter baumannii infections;Garnacho-Montero;Curr Opin Infect Dis,2019

2. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin;Katsube;Clin Infect Dis,2019

3. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial;Bassetti;Lancet Infect Dis,2021

5. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients;Falcone;Clin Infect Dis,2021

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis;BMC Infectious Diseases;2024-09-13

2. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

3. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

4. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study;European Journal of Clinical Microbiology & Infectious Diseases;2024-04-18

5. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis;Journal of Infection;2024-03